Company intelligence / Profile preview
Beacon Therapeutics
Alachua, Florida, United Statesbeacontx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead asset AGTC-501 has shown promising results in clinical trials for XLRP, with 24-month data from the SKYLINE trial demonstrating favorable safety profile and robust improvements in mean retinal sensitivity. The therapy is currently being evaluated in multiple clinical trials including the registrational VISTA trial, DAWN trial, and HORIZON trial.
- Therapeutic areas
- Ophthalmology
- Modalities
- Gene therapyAdeno-associated virus (AAV) gene therapy
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Beyond the preview
Go deeper on Beacon Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beacon Therapeutics.